In the US Food and Drug Administration (FDA) study, officials combed through vaccine reaction data on two RSV jabs, called Abrysvo and Arexvy, documented between May 2023 and July last year.

The regulator is due to make a decision on Pfizer’s rival vaccine Abrysvo later this month. Getting FDA approval is just the first hurdle for the two vaccines, however. Assuming they are both ...

Any suspected adverse events related to Abrysvo or Arexvy may be reported to the Vaccine Adverse Event Reporting System. “There is still uncertainty regarding the amount of increased GBS risk ...

The vaccine in play — called Abrysvo — was registered for use in pregnancy by the regulator that approves medicines, the Therapeutic Goods Administration (TGA), in March. Professor Bennett ...

In the abrysvo or arexvy market, companies aim to expand the vaccine's use across a wider range of age groups by focusing on broader age indications. An example is Pfizer Inc., which received FDA ...

On the flip side, vaccines Prevnar and Abrysvo underperformed expectations. Pfizer expects $1B hit from IRA's Part D redesign and no major M&A in 2025 RSV vaccine Abrysvo specifically floundered ...

Pregnant women can now get the maternal RSV vaccine, Abrysvo, for free under the National Immunisation Program (NIP), alongside ones for influenza and whooping cough. Abrysvo is available for ...

Two RSV vaccines were approved for use in Australia last year by the Therapeutic Goods Administration. The Australian Government is funding Pfizer’s Abrysvo for pregnant women and, in an unusual ...

Bavarian Nordic’s chikungunya vaccine Vimkunya is one step closer to being available in Europe after having secured an European Medicines Agency (EMA) recommendation for a marketing authorisation.